Loading
Life sciences · Journal article
Advanced Healthcare Materials · October 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Patient‐derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with high target specificity, yet their application in organoid systems remains underexplored. Here, we adapted previously described protocols to establish a biobank of prostate cancer (PC) PDOs, achieving a high initial growth success rate (>90%). Histological and molecular analyses confirmed the preservation of key tumor features. Using these models, we assessed several ASOs, with particular emphasis on OGX‐427 (Apatorsen), an ASO targeting heat shock protein 27 (HSP27) that has been evaluated in phase I/II clinical trials. While OGX‐427 effectively suppressed HSP27 expression and inhibited cell growth in 2D cultures, its efficacy was markedly limited in 3D organoids, likely due to extracellular matrix and structural barriers. Removing Matrigel and applying single‐cell transfection overcame these barriers, achieving efficient ASO uptake, significant target protein downregulation, and robust, dose‐dependent inhibition of organoid growth. These findings underscore the utility of PDOs for evaluating ASO‐based therapies and their potential to accelerate precision oncology strategies for PC and other malignancies.